Jane de Lartigue, PhD

Articles

Cleveland Clinic Researcher Recaps Successes and Stumbles in Dual HER2 Targeting

September 25th 2017

Although dual HER2 blockade strategies have become an important part of the treatment paradigm for patients with HER2-positive breast cancer, the complexities of administering these therapies continue to unfold.

Finding the Right Place for Dual HER2 Blockade in Breast Cancer and Beyond

September 4th 2017

Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.

TRK Inhibitors Advance Rapidly in "Tumor-Agnostic" Paradigm

August 4th 2017

The growing use of next-generation sequencing has only recently revealed the neurotrophic tropomyosin receptor kinase (NTRK) gene presence across a wide range of tumor types and piqued interest in their potential as anticancer targets.

Blurring the Lines Between Germline and Somatic Mutations in Cancer

July 7th 2017

Many challenges remain to the optimal interpretation of genetic test results and the effective translation of these data into improved diagnostic, prognostic, and therapeutic capabilities.

Leukemia Researcher Sees Exciting Prospects for New Targeted Agents

June 1st 2017

Jeff Sharman, MD, discusses the prospects for progress in targeting elements of the BCR pathway.

B-Cell Receptor Signaling Pathway Emerges as Ripe Target in Many Cancers

May 25th 2017

Despite the availability of numerous effective treatment options, most patients with B-cell malignancies still experience frequent relapses and progressively shorter remissions, creating a pressing need for new drugs to add to the therapeutic arsenal.

Gene Fusions Yield Increasingly Broad Spectrum of Targeted Therapies

May 3rd 2017

Thus far, only a small portion of known gene fusions have been tested with functional assays in an effort to understand if, and how, they drive cancer. Newly identified and well-established gene fusions alike continue to provide promising therapeutic targets and broaden our understanding of cancer development.

Beyond Myeloma: New Roles for IMiDs

April 10th 2017

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.

OX40 Agonists Forge a Path in Combination Immunotherapy

March 2nd 2017

Promising reports of preclinical and early clinical data in 2016 are poised to further boost the development of rational combinations of OX40 agonists with checkpoint immunotherapies, surgical resection, radiotherapy, and even the potential for 3-drug cocktails.

TIGIT Emerges as New Target for Immune Checkpoint Blockade Strategies

February 9th 2017

As researchers continue to identify a growing number of immune checkpoints as targets for anticancer therapy, the recently discovered TIGIT pathway is emerging as a promising new avenue for exploration.

KIR Strategies Face Many Hurdles

December 31st 2016

Don M. Benson Jr, MD, PhD, discusses the clinical development of KIR-targeted therapies.

Targeting KIR Opens Door to Promising Immunotherapy Combos

December 30th 2016

Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.

Mutational Complexity Reflects Treatment Challenges for Hepatocellular Carcinoma

December 19th 2016

The growing incidence of primary liver cancer in the United States poses a great therapeutic challenge.

DNA Repair Defects Emerge as a New Category for Anticancer Therapies

December 2nd 2016

A coordinated network of signaling pathways works to protect the cell from the toxic effects of DNA damage.

It's Time to Move Beyond the Genome in Breast Cancer

December 2nd 2016

Matthew J. Ellis, MB BChir, PhD, FRCP, provides his expertise on the genomics and molecular profiling of breast cancer.

Despite Progress, More Actionable Mutations Needed in Lung Cancer

December 2nd 2016

Despite these successes, driver mutations have been identified in only a minority of cases and patients with other types of lung cancer, such as squamous cell carcinoma and small-cell lung cancer, do not currently benefit from targeted therapies.

Targeting CD47 May Open "Exciting" Door to Novel Combos

November 3rd 2016

Gregory L. Beatty, MD, PhD, who focuses his research on understanding the role of innate immunity in gastrointestinal malignancies, discusses CD47 as an anticancer target.

CD47 Studies Take Immunotherapy in New Direction

October 31st 2016

During the past several decades, it has become increasingly clear that there is a complicated relationship between a tumor and the patient’s immune system. Although the genetic and epigenetic changes that fuel cancer development create foreign antigens that should trigger an immune response, one of the hallmarks of cancer is its ability to evade this immune recognition.

Breast Cancer's Complexity Pushes Researchers to Look Beyond the Genome

October 25th 2016

Although breast cancer research has helped chart the course for molecularly targeted therapies in oncology, next-generation sequencing technologies have revealed a disease so highly complex and heterogeneous that translating these findings into clinically useful therapies has proved daunting.

Wistar Scientist Sees Many Potential Avenues in MDSC Research

October 7th 2016

Dmitry I. Gabrilovich, MD, PhD, provides perspective on understanding the role of the tumor microenvironment in the regulation of the immune response in cancer, with a focus on myeloid cells.